COMP <GO>
BMY vs GSK // EV/EBITDA & P/E VALUATION
Bristol-Myers Squibb Company (NYSE) VS. GSK plc American (NYSE) • 15-METRIC TALLY: BMY 10
— GSK 3
▲ EV/EBITDA & P/E VALUATION LEADER: BMY
LAST: $62.48 (+1.78%) • MKT CAP: $125.40B
valuation
16.3x
LAST: $49.51 (+1.71%) • MKT CAP: $98.47B
valuation
21.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMY VS. GSK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMY | GSK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.30% | 9.90% | +3.40 | BMY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 16.3x | 21.0x | -4.70 | BMY | /valuation <GO> |
| Free Cash Flow Yield | 10.24% | 2.21% | +8.03 | BMY | /fcf-yield <GO> |
| Operating Margin | 17.90% | 13.90% | +4.00 | BMY | /operating-margins <GO> |
| Net Profit Margin | 14.60% | 10.90% | +3.70 | BMY | /net-margins <GO> |
| Revenue Growth (YoY) | -0.20% | 8.80% | -9.00 | GSK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.02% | 0.00% | +4.02 | BMY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 3.74 | -1.50 | GSK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | GSK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.4 | 46.8 | +3.60 | BMY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.95 | +0.03 | BMY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.6x | 30.5x | -13.90 | BMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $125.40B | $98.47B | $26.94B | BMY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMY REV | GSK REV | BMY GROSS % | GSK GROSS % | BMY FCF | GSK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $48.19B | — | 71.1% | — | $12.85B | — |
| FY 2024 | $48.30B | — | 71.1% | — | $13.94B | — |
| FY 2023 | $45.01B | — | — | — | $11.83B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMY // BETA 0.98
GSK // BETA 0.95